title: Beta-sarcoglycan gene mutations in Turkey.
abstract: The term limb-girdle muscular dystrophy (LGMD) refers to a group of muscular dystrophies that, at the outset, affect primarily the muscles of the hip and shoulder girdle. Limb-girdle muscular dystrophy is genetically heterogeneous comprising autosomal dominant (types LGMD 1A-1E) as well as autosomal recessive forms (types LGMD 2A-2J known). A subgroup among the autosomal recessive forms comprises the sarcoglycanopathies (LGMD2C-2F), caused by mutations in the gamma (gamma-SG), alpha (alpha-SG), beta (beta-SG) and delta (delta-SG) sarcoglycan genes, respectively. The sarcoglycans form the sarcoglycan complex, part of the dystrophin-associated glycoproteins. Mutations in the beta-SG gene causes LGMD2E. Disease severity, in this form, varies from mild to severe phenotypes depending on the individual mutation. Homozygous missense mutations in critical locations may result in the total absence of alpha-, beta- and gamma-sarcoglycan from the muscle membrane and a phenotype as severe as null mutations. In the present study, through screening 80 unrelated LGMD2 families, we identified 13 families with LGMD2E. Mutations in the beta-SG gene were identified in 12 patients from nine families. One of these patients carried a previously reported truncating mutation (Q11X), while the other 11 carried novel missense/rameshift mutations (M1L, V89M, I92T, I92S, 739insA), some of which were seen in more than one patient and may, therefore, be more common in the Turkish population.
authors.affiliation: Hacettepe University, Faculty of Medicine, Department of Medical Biology, Turkey.
authors.forename: B
authors.initials: B
authors.lastname: Balci
authors.forename: E
authors.initials: E
authors.lastname: Wilichowski
authors.forename: G
authors.initials: G
authors.lastname: Haliloğlu
authors.forename: B
authors.initials: B
authors.lastname: Talim
authors.forename: S
authors.initials: S
authors.lastname: Aurino
authors.forename: E
authors.initials: E
authors.lastname: Kremer
authors.forename: F
authors.initials: F
authors.lastname: Ebinger
authors.forename: N
authors.initials: N
authors.lastname: Senbil
authors.forename: B
authors.initials: B
authors.lastname: Anlar
authors.forename: G
authors.initials: G
authors.lastname: Kale
authors.forename: V
authors.initials: V
authors.lastname: Nigro
authors.forename: H
authors.initials: H
authors.lastname: Topaloğlu
authors.forename: C
authors.initials: C
authors.lastname: Bonnemann
authors.forename: P
authors.initials: P
authors.lastname: Dinçer
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D015331:Cohort Studies; D005091:Exons / Q000235:genetics; D005260:Female; D008040:Genetic Linkage / Q000235:genetics; D006801:Humans; D008297:Male; D049288:Muscular Dystrophies, Limb-Girdle / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D010641:Phenotype; D049031:Sarcoglycans / Q000235:genetics*; D012720:Severity of Illness Index; D014421:Turkey
chemical_list: D049031:Sarcoglycans